Lifeboat Foundation

CytoDyn Inc. announced in a news release last week that its ongoing extension study of PRO 140 monotherapy has shown “complete viral-load suppression” for well over a year, with some patients approaching 17 months. The phase I trial included 23 patients.

“The company believes that complete virologic suppression through treatment with a single agent, PRO 140, a safe and efficacious antibody, rather than through the widely used HAART combination therapy, could present a significant opportunity to treat HIV patients. Based on these monotherapy results, the company plans to file a second Phase 3 protocol for PRO 140 monotherapy with the FDA. CytoDyn is currently conducting a pivotal phase 3 trial for PRO 140 as an adjunct therapy with expected commercialization in 2017.”

On Jan 22, the company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment experienced patients with virologic failure, meaning other medications alone no longer work for them.

Read more

Very interesting discovery about how our brain thinks; our brain isn’t always 100% error proof according to this report from Carnegie Mellon University. Therefore, when researchers are mapping the brain plus mimicking human brain functions; what is the tolerance level for error allowed then?

A study conducted at Carnegie Mellon University investigated the brain’s neural activity during learned behavior and found that the brain makes mistakes because it applies incorrect inner beliefs, or internal models, about how the world works. The research suggests that when the brain makes a mistake, it actually thinks that it is making the correct decision—its neural signals are consistent with its inner beliefs, but not with what is happening in the real world.

“Our brains are constantly trying to predict how the world works. We do this by building internal models through experience and learning when we interact with the world,” said Steven Chase, an assistant professor in the Department of Biomedical Engineering and the Center for the Neural Basis of Cognition. “However, it has not yet been possible to track how these internal models affect instant-by-instant behavioral decisions.”

Continue reading “Mental Miscues” »

Building building diamond lattices through DNA.

Using bundled strands of DNA to build Tinkertoy-like tetrahedral cages, scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have devised a way to trap and arrange nanoparticles in a way that mimics the crystalline structure of diamond. The achievement of this complex yet elegant arrangement, as described in a paper published February 5, 2016, in Science, may open a path to new materials that take advantage of the optical and mechanical properties of this crystalline structure for applications such as optical transistors, color-changing materials, and lightweight yet tough materials.

“We solved a 25-year challenge in building diamond lattices in a rational way via self-assembly,” said Oleg Gang, a physicist who led this research at the Center for Functional Nanomaterials (CFN) at Brookhaven Lab in collaboration with scientists from Stony Brook University, Wesleyan University, and Nagoya University in Japan.

Continue reading “DNA used to assemble nanoparticles into a copy of the crystalline structure of diamond” »

Tough to be a doctor these days — Could be bad news for Providers with limited or no Cyber Risk Coverage.

Providers are focusing on cybersecurity with increased urgency. Cyberattacks on health-care organizations reached an all-time high in 2015 and aren’t expected to slow down in 2016, Harry Greenspun, director for Deloitte’s Center for Health Solutions, told Bloomberg BNA. One element of a comprehensive strategy to address data security is customized cyber risk insurance. Recent case law supports standing for class action litigants alleging future injuries, which may not be covered by some policy forms. We urge providers to review their cyber risk coverage with the increasing risks and this new case law in mind.

Specifically, it is critical that cyber risk insurance is designed to both: adequately mitigate future harm to those whose private information is compromised as a result of a data breach; and satisfy the full array of damages sought by such third parties, including damages for future injuries resulting from the anticipated improper use of data. These considerations are increasingly important because the policies available in today’s market are not standardized. While many absorb some of the costs associated with notification and fraud monitoring, existing forms may not protect against damages sought for susceptibility to identity theft.

Continue reading “Are you covered? Emerging issues for health care providers under cyber risk insurance” »

Graphene; the material for brain chip implants; however, Q-Dots ferrofluid is where it will make us totally rethink brain implants in the future.

A new technology developed by researchers in Italy and the United Kingdom allows for the creation of graphene-based materials that can be interfaced with neurons without losing its electrical conductivity. This can lead to the creation of neural electrodes that are not only biocompatible, but stable within the body as well. (Photo : University of Cambridge)

Scientists from the United Kingdom and Italy have developed a new process in which a carbon form known as graphene is combined with neurons without sacrificing the integrity of these cells.

Continue reading “Graphene Brain Implants May Help Patients Regain Sensory Functions And Control Motor Disorders” »

A new study has shown that the lifespans of mice can be extended by up to 35 percent by simply clearing out senescent cells — defunct cells that stop dividing, accumulate in old age, and trigger inflammation in fat, muscle, and kidney tissues.

Not only did the mice experience significantly longer lifespans thanks to removal of these cells, but the treatment also delayed the onset of age-related disorders such as heart and kidney deterioration, and the development of cataracts and tumours.

“It’s not just that we’re making these mice live longer; they actually stay healthier longer too. That’s important, because if you were going to equate this to people, well, you don’t want to just extend the years of life that people are miserable or hospitalised,” one of the team, cell biologist Darren Barker from the Mayo Clinic College of Medicine, told William Herkewitz at Popular Mechanics.

Read more

Ampakines are known mental stimulants, but in rats they can also shelter the brain from age-related decline and even reverse deterioriation

A number of changes happen in the aging brain and one of these is a dendritic loss which onsets around middle age. In a new study, researchers have shown a particular drug belonging to the ampakine class of compounds, has significant neuroprotective properties.

Shielding the brain

Continue reading “Nootropic Drug Can Reverse And Prevent Cognitive Decline In Rats” »

By David Patterson Professor of Computer Science University of California, Berkeley This ancient assassin, first identified by a pharaoh’s physician, has been killing people for more than 4,600 years. As scientists found therapies for other lethal diseases–such as measles, influenza, and heart disease–cancer moved up this deadly list and will soon be #1; 40% of Americans will face cancer during their lifetimes, with half dying from it. Most of us ignore cancer until someone close is diagnosed, but instead society could zero in on this killer by recording massive data to discover better treatments before a loved one is in its crosshairs.

Cancer is unlimited cell growth caused by problems in DNA. Some people are born with precarious DNA, and others acquire it later. When a cell divides, sometimes it miscopies a small amount of its DNA, and these errors can overwhelm a cell’s defenses to cause cancer. Thus, you can get it without exposure to carcinogens. Cigarettes, radiation, asbestos, and so on simply increase the copy error rate. Speaking figuratively, every time a cell reproduces, we roll the dice on cancer, with such mutagens loading the dice to raise cancer’s chances.

Most cancer studies today use partial genomic information and have fewer than 1,000 patients. One wonders whether their conclusions would still hold if they used complete genomes and increased the number of patients by factors of 10–100.

Read more

New study identifies genetic variants associated with preference to mornings or nights.

Read more